| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Feb 2026 | 6 Feb 2026 |
| Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months period ended 31 December 2025. On recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, appointed Mr. Paritosh Trivedi (A63623) as Company Secretary, Compliance Officer and Nodal Officer of the Company with effect from February 11, 2026. The Board of Directors of the Company, at its meeting held today i.e. Wednesday, February 11, 2026, has inter-alia; 1. UNAUDITED FINANCIAL RESULTS : On review and recommendation of Audit Committee of the Company the Board approved Unaudited Standalone and Consolidated Financial Results for the Third quarter and Nine months ended on December on 31, 2025. 2. APPOINTMENT OF KEY MANAGERIAL PERSONNEL On the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, appointed Mr. Paritosh Trivedi (A63623) as Company Secretary, Compliance Officer and Nodal Officer of the Company with effect from February 11, 2026. (As per BSE announcement dated on : 11.02.2026) | ||
| Board Meeting | 18 Dec 2025 | 18 Dec 2025 |
| Appointment of Mr. Raviraj Karia as Chief Financial Officer and KMP | ||
| Board Meeting | 13 Nov 2025 | 8 Nov 2025 |
| Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and six months period ended 30 September 2025. 1. Approval of Q2 FY26 Financial results 2. Upon recommendation of Audit committee, board approved to Invest by way of acquiring 100 % equity share capital of M/s Celliimune Biotech Private Limited. 3. Upon recommendation of Audit committee, board approved invest upto Rs. 10 Crores in Captive Hybrid Solar Power Project for Limbasi Plant by entering into an agreement with relevant party. (As Per BSE Announcement Dated on 13.11.2025) | ||
| Board Meeting | 8 Aug 2025 | 4 Aug 2025 |
| Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the First quarter ended on June 30 2025 along with limited review report Outcome of Board Meeting held today , Friday, August 08, 2025- Unaudited Financial Results for the First quarter ended on June 30, 2025 (As per BSE Announcement Dated on 08.08.2025) | ||
| Board Meeting | 29 May 2025 | 23 May 2025 |
| Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve the audited Standalone and Consolidated Financial results of the company for the quarter and year ended March 31 2025 Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May2025 The Board has recommended Dividend of Rs. 10.70 per Equity Share of face value of Re. 1 each fully paid up for the Financial Year 2024-25, subject to approval by shareholders of the Company at the ensuing AGM. Outcome of Board Meeting held today i.e. Thursday, May 29, 2025- To Audited Financial Results for the quarter and Financial Year ended on March 31, 2025 and to approve other agendas. (As Per BSE Announcement Dated on 29.05.2025) | ||
Here are some of the stocks that may see significant price movement today: Concord Biotech, NTPC, Vodafone Idea, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
